Tanvex CDMO
Mammalian & Microbial Biologics and Biosimilars Development & Manufacturing – CDMO
Goals & Objectives
Tanvex CDMO specializes in the development and manufacture of mammalian and microbial-based biologics. After its parent company had successfully commercialized two biosimilars, the Taiwanese owners sought to maximize capacity utilization and optimize revenue by establishing an embedded CDMO business in the US.
Strategic Approach
That’s Nice developed a market strategy for Tanvex CDMO that utilized the parent company’s reputation for quality and its team’s experience in biologics development from IND to BLA. Moreover, Tanvex’s California facility allowed it to capitalize on the industry’s growing demand for supply chain security through domestic US manufacturing.
Meeting & Exceeding KPIs
The Tanvex CDMO brand formally launched in 2023 with resounding success, establishing a CDMO foothold in the Western market. The new brand successfully captured the existing prestige of the parent company’s heritage but was differentiated enough to stand on its own.
